Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: Influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4422-4427

  Rose, Warren E ^a   Fallon, Michael ^b   Moran, John J M ^a   Vanderloo, Joshua P ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; TELAVANCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; EARLY RESPONSE GENE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PHENOTYPE; PRIORITY JOURNAL;

AMINOACYLTRANSFERASES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DAPTOMYCIN; DNA-BINDING PROTEINS; DRUG TOLERANCE; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84864386773     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00676-12     Document Type: Article

References (33)

1. Cafiso V, et al. 2012. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. PLoS One 7:e29573. doi:10.1371/journal.pone.0029573.
2. Clinical and Laboratory Standards Institute. 2010. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K. 2000. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob. Agents Chemother. 44:2276-2285. (Pubitemid 30650868)
4. Cui L, Neoh HM, Shoji M, Hiramatsu K. 2009. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 53:1231-1234.
5. Fischer A, et al. 2011. Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J. Antimicrob. Chemother. 66:1696-1711.
6. Friedman L, Alder JD, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145. (Pubitemid 43807536)
7. Higgins DL, et al. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134. (Pubitemid 40327734)
8. Holmes NE, et al. 2011. Antibiotic choice may not explain poorer out-comes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J. Infect. Dis. 204:340-347.
9. Honda H, Doern CD, Michael-Dunne W, Jr, Warren DK. 2011. The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia. BMC Infect. Dis. 11:335. doi:10.1186/1471-2334-11-335.
10. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. 2006. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50:3039 -3047.
11. Howden BP, et al. 2008. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol. 8:39. doi:10.1186/1471-2180-8-39.
12. Jones RN. 2006. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 42(Suppl 1):S13-S24. (Pubitemid 41832061)
13. Jones T, et al. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52:269-278.
14. Kosowska-Shick K, et al. 2009. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob. Agents Chemother. 53:4217-4224.
15. Kullar R, Davis SL, Levine DP, Rybak MJ. 2011. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52:975-981.
16. Lina G, et al. 2003. Bacterial competition for human nasal cavity colonization: role of staphylococcal agr alleles. Appl. Environ. Microbiol. 69:18-23. (Pubitemid 36077452)
17. Lodise TP, et al. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
18. MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE. 2011. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. Antimicrob. Agents Chemother. 55:867-873.
19. Mehta S, et al. 2012. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivoselected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 56:92-102.
20. Moise PA, et al. 2010. Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes. J. Infect. Dis. 201:233-240.
21. Moise-Broder PA, et al. 2004. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38:1700-1705. (Pubitemid 38781661)
22. Rose WE, Kaatz GW, Sakoulas G, Rybak MJ. 2008. Teicoplanin pharmacodynamics in reference to the accessory gene regulator (agr) in Staphylococcus aureus using an in vitro pharmacodynamic model. J. Antimicrob. Chemother. 61:1099-1102. (Pubitemid 351524456)
23. Rose WE, Knier RM, Hutson PR. 2010. Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus. J. Antimicrob. Chemother. 65:2149-2154.
24. Sader HS, Jones RN, Rossi KL, Rybak MJ. 2009. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J. Antimicrob. Chemother. 64:1024-1028.
25. Sakoulas G, et al. 2005. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob. Agents Chemother. 49:2687-2692. (Pubitemid 40917579)
26. Sakoulas G, et al. 2003. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J. Infect. Dis. 187:929 -938.
27. Sakoulas G, et al. 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492-1502. (Pubitemid 34415333)
28. Schweizer ML, et al. 2011. Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients. Antimicrob. Agents Chemother. 55:1082-1087.
29. Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. 1982. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann. Intern. Med. 97:344-350.
30. Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. 2007. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:1089-1091. (Pubitemid 46355301)
31. Yang SJ, et al. 2009. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J. Infect. Dis. 200:1916-1920.
32. Yang SJ, et al. 2009. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 53:2636-2637.
33. Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ. 2010. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J. Antimicrob. Chemother. 65:1015-1018.